• In the US, the Centers for Disease Control and Prevention has estimated that 2 million patients a year suffer from infections due to drug resistant bacteria and antimicrobial resistance is predicted to result in 10 million deaths worldwide by 2050.
• Growing antimicrobial resistance combined with a dry antibiotic pipeline has led clinicians to utilize older antibiotics that can be more toxic and/or ineffective.
There has been development and regulatory progress made, but this is leading to an increasing number of antibiotics that will be reaching the market with limited datasets. Clinicians should understand how to best interpret and incorporate the data into clinical decision-making.
• Clinicians should understand the various challenges for the decline in antibiotic development and understand the initiatives that are currently in place to help fix the issues as well as further potential solutions.
